Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Jornal de Pediatria

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jpeds.2014.12.015PMID 25641239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment and impact of dyslipidemia in diabetic nephropathy

  2013cited by this paper
• Protective effects of tocotrienols against lipid-induced nephropathy in experimental type-2 diabetic rats by modulation in TGF-β expression.

  2013cited by this paper
• Multiple lipid-lowering treatment in pediatric patients with hyperlipidemia.

  2012cited by this paper
• Oxidative stress mediates nephropathy in type Ia glycogen storage disease

  2010cited by this paper
• Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

  2009cited by this paper
• Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia.

  2008cited by this paper
• Efficacy of ACE‐inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study

  2005cited by this paper
• Preventing microalbuminuria in type 2 diabetes.

  2004cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression.

  2001cited by this paper
• GLYCOGEN STORAGE DISEASE.

  1964cited by this paper

• Kidney involvement in glycogen storage disease type I: Current knowledge and key challenges.

  2025cites this paper
• Multiomics approach provides insight into altered choline metabolism and liver injury in patients with glycogen storage disease type Ia

  2025cites this paper
• Integral kidney function assessment in pediatric patients with glycogen storage diseases

  2025cites this paper
• Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization

  2024cites this paper
• Endocrine Complications in Hepatic Glycogen Storage Diseases: A Long-term Perspective

  2024cites this paper
• A specific serum lipid signature characterizes patients with glycogen storage disease type Ia

  2024cites this paper
• Glycogen storage disease type 1a in the Ohio Amish

  2022cites this paper
• Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report

  2021cites this paper
• Clinical, Biochemical and Molecular Characterization of a Cohort of Glycogen Storage Disease Type I Patients in a High Complexity Hospital in Argentina

  2021cites this paper
• Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients

  2021cites this paper
• Over 20-Year Follow-up of Patients with Hepatic Glycogen Storage Diseases: Single-Center Experience

  2020cites this paper
• Glycogen storage disease type І: peculiarities of clinical course, diagnostics and nutritive support on modern stage

  2020cites this paper
• An infant presenting with extreme hypertriglyceridemia diagnosed as glycogen storage disease type Ia

  2020cites this paper
• Glycemic control and complications in glycogen storage disease type I: Results from the Swiss registry.

  2019cites this paper
• Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III

  2019cites this paper
• A preliminary study of telemedicine for patients with hepatic glycogen storage disease and their healthcare providers: from bedside to home site monitoring

  2018cites this paper
• Review shows that lipid disorders are associated with endothelial but not renal dysfunction in children

  2018cites this paper
• Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control

  2017cites this paper
• Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy

  2017cites this paper
• Progressive development of renal cysts in glycogen storage disease type I.

  2016cites this paper